SEC Company Response from Zentalis Pharmaceuticals, Inc. (ZNTL) (CIK 0001725160) (ZNTL) — Mar 31, 2020
Zentalis Pharmaceuticals, Inc. (ZNTL) (CIK 0001725160)
Date: March 31, 2020 · CIK: 0001725160 · Accession: 0001193125-20-092892
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-236959
Letter
Via EDGAR Transmission United States Securities and Exchange Commission Division of Corporation Finance Attention: Chris Edwards Zentalis Pharmaceuticals, LLC Registration Statement on Form S-1 Filed March 6, 2020 Registration No. 333-236959
Dear Mr. Edwards:
In accordance with Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, we hereby request the acceleration of the effective date of the above-referenced Registration Statement so that it will become effective on April 2, 2020, at 4:00 p.m., Eastern Time, or as soon thereafter as practicable, or at such later time as Zentalis Pharmaceuticals, LLC (the “Company”) or its counsel may request via telephone call to the staff. Please contact Nathan Ajiashvili of Latham & Watkins LLP, counsel to the Company, at (212) 906-2916, or in his absence, Salvatore Vanchieri at (212) 906-4605, to provide notice of effectiveness, or if you have any other questions or concerns regarding this matter.
Sincerely yours,
Zentalis Pharmaceuticals, LLC
Show Raw Text
CORRESP 1 filename1.htm CORRESP March 31, 2020 Via EDGAR Transmission United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Mail Stop 4720 Washington, D.C. 20549 Attention: Chris Edwards Re: Zentalis Pharmaceuticals, LLC Registration Statement on Form S-1 Filed March 6, 2020 Registration No. 333-236959 Dear Mr. Edwards: In accordance with Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, we hereby request the acceleration of the effective date of the above-referenced Registration Statement so that it will become effective on April 2, 2020, at 4:00 p.m., Eastern Time, or as soon thereafter as practicable, or at such later time as Zentalis Pharmaceuticals, LLC (the “Company”) or its counsel may request via telephone call to the staff. Please contact Nathan Ajiashvili of Latham & Watkins LLP, counsel to the Company, at (212) 906-2916, or in his absence, Salvatore Vanchieri at (212) 906-4605, to provide notice of effectiveness, or if you have any other questions or concerns regarding this matter. Sincerely yours, Zentalis Pharmaceuticals, LLC By: /s/ Anthony Y. Sun Anthony Y. Sun, M.D. President and Chief Executive Officer cc: Nathan Ajiashvili, Esq. Salvatore Vanchieri, Esq.